![](/img/cover-not-exists.png)
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145
Michael J. Kovacs, Donna E. Reece, Deborah Marcellus, Ralph M. Meyer, Sarah Mathews, Rui-Ping Dong, Elizabeth EisenhauerVolume:
24
Language:
english
Pages:
7
DOI:
10.1007/s10637-006-9022-7
Date:
November, 2006
File:
PDF, 685 KB
english, 2006